Hypoxia and Extracellular Acidification as Drivers of Melanoma Progression and Drug Resistance.
acidification
drug resistance
hypoxia
immune escape
invasiveness
melanoma
tumor microenvironment
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
09 04 2021
09 04 2021
Historique:
received:
03
03
2021
revised:
31
03
2021
accepted:
07
04
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
21
10
2021
Statut:
epublish
Résumé
Hypoxia and elevated extracellular acidification are prevalent features of solid tumors and they are often shown to facilitate cancer progression and drug resistance. In this review, we have compiled recent and most relevant research pertaining to the role of hypoxia and acidification in melanoma growth, invasiveness, and response to therapy. Melanoma represents a highly aggressive and heterogeneous type of skin cancer. Currently employed treatments, including BRAF V600E inhibitors and immune therapy, often are not effective due to a rapidly developing drug resistance. A variety of intracellular mechanisms impeding the treatment were discovered. However, the tumor microenvironment encompassing stromal and immune cells, extracellular matrix, and physicochemical conditions such as oxygen level or acidity, may also influence the therapy effectiveness. Hypoxia and acidification are able to reprogram the metabolism of melanoma cells, enhance their survival and invasiveness, as well as promote the immunosuppressive environment. For this reason, these physicochemical features of the melanoma niche and signaling pathways related to them emerge as potential therapeutic targets.
Identifiants
pubmed: 33918883
pii: cells10040862
doi: 10.3390/cells10040862
pmc: PMC8070386
pii:
doi:
Substances chimiques
Acids
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Narodowe Centrum Nauki
ID : 2018/29/B/NZ5/00967
Références
Front Immunol. 2020 Sep 30;11:586977
pubmed: 33117401
Urol Oncol. 2018 Jun;36(6):311.e1-311.e13
pubmed: 29602637
Oncol Rep. 2018 Jun;39(6):2855-2864
pubmed: 29693169
Blood. 2007 May 1;109(9):3812-9
pubmed: 17255361
Nat Rev Cancer. 2011 Aug 11;11(9):671-7
pubmed: 21833026
J Immunol. 2010 Dec 1;185(11):6413-9
pubmed: 21084670
Cancer Cell Int. 2013 Sep 03;13(1):89
pubmed: 24004445
Oncotarget. 2018 Feb 16;9(18):14567-14579
pubmed: 29581864
Balkan Med J. 2019 Oct 09;37(1):15-23
pubmed: 31594284
Am J Cancer Res. 2015 Jan 15;5(2):792-801
pubmed: 25973316
Cancer Lett. 2017 Nov 1;408:43-54
pubmed: 28826720
Cancer Immunol Immunother. 2019 Aug;68(8):1287-1301
pubmed: 31253998
Mol Oncol. 2014 Dec;8(8):1365-78
pubmed: 24954857
Transl Oncol. 2014 Apr;7(2):206-12
pubmed: 24746711
Cancer Res. 2012 Sep 15;72(18):4629-41
pubmed: 22962263
J Transl Med. 2017 Nov 28;15(1):241
pubmed: 29183378
Proc Natl Acad Sci U S A. 2016 Sep 6;113(36):E5344-53
pubmed: 27543333
Oncotarget. 2017 Oct 30;8(65):108786-108801
pubmed: 29312568
Cancer Immunol Res. 2019 Jul;7(7):1064-1078
pubmed: 31088846
Biochem Biophys Res Commun. 2018 Jul 2;501(4):885-892
pubmed: 29763606
Melanoma Res. 1997 Oct;7(5):400-6
pubmed: 9429223
Pigment Cell Melanoma Res. 2016 Sep;29(5):508-23
pubmed: 27233233
Cell Death Differ. 2008 Apr;15(4):621-7
pubmed: 18259201
Anticancer Res. 2018 Dec;38(12):6745-6752
pubmed: 30504385
Br J Pharmacol. 2019 Jul;176(14):2509-2524
pubmed: 30874296
Nat Rev Cancer. 2019 Jul;19(7):377-391
pubmed: 31209265
Small. 2018 Jul;14(28):e1801120
pubmed: 29882235
J Clin Lab Anal. 2021 Feb;35(2):e23622
pubmed: 33118214
J Mol Med (Berl). 2020 Oct;98(10):1431-1446
pubmed: 32803272
Clin Exp Metastasis. 2008;25(4):411-25
pubmed: 18301995
Mol Cancer. 2009 Nov 17;8:104
pubmed: 19919690
Biochem Biophys Res Commun. 2018 Feb 19;496(4):1357-1361
pubmed: 29421654
Cancer Immunol Res. 2017 Jun;5(6):455-467
pubmed: 28468914
Cancer Res. 2013 Mar 1;73(5):1524-35
pubmed: 23288510
Cancer Res. 1999 Nov 15;59(22):5830-5
pubmed: 10582706
Biomedicines. 2018 May 15;6(2):
pubmed: 29762526
PLoS One. 2011 Jan 19;6(1):e15746
pubmed: 21283814
J Physiol. 2007 Dec 1;585(Pt 2):351-60
pubmed: 17916606
PLoS One. 2012;7(3):e32989
pubmed: 22457728
Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5510-4
pubmed: 7539918
Clin Cancer Res. 2018 Jun 1;24(11):2482-2490
pubmed: 29420223
J Biol Chem. 2011 Apr 15;286(15):13438-47
pubmed: 21349841
Nat Rev Cancer. 2017 Aug;17(8):457-474
pubmed: 28706266
J Biol Chem. 2005 Mar 25;280(12):10938-44
pubmed: 15657063
Nat Rev Cancer. 2004 Nov;4(11):891-9
pubmed: 15516961
Mol Cell Biol. 2016 Jan 19;36(7):1090-108
pubmed: 26787841
Cancer Res. 2019 Feb 1;79(3):518-533
pubmed: 30573518
Mol Cancer Ther. 2002 Jun;1(8):617-28
pubmed: 12479222
Biosci Rep. 2019 Jan 8;39(1):
pubmed: 30487162
Clin Exp Metastasis. 2019 Jun;36(3):171-198
pubmed: 30972526
Front Oncol. 2019 Feb 06;9:43
pubmed: 30788287
J Invest Dermatol. 2011 Sep;131(9):1793-805
pubmed: 21633368
Nat Immunol. 2018 Dec;19(12):1319-1329
pubmed: 30397348
Front Immunol. 2018 Jan 22;9:14
pubmed: 29403496
Invest Ophthalmol Vis Sci. 2014 Mar 04;55(3):1277-83
pubmed: 24481264
Cancers (Basel). 2020 Mar 14;12(3):
pubmed: 32183388
Oncoimmunology. 2016 Aug 12;5(10):e1219826
pubmed: 27853641
Pflugers Arch. 2009 Oct;458(6):1069-83
pubmed: 19562366
Br J Cancer. 2007 Apr 10;96(7):1072-82
pubmed: 17342088
Biochem Pharmacol. 2003 Oct 1;66(7):1207-18
pubmed: 14505800
FASEB J. 2007 Apr;21(4):976-94
pubmed: 17242160
Genes Dev. 2016 May 1;30(9):1002-19
pubmed: 27151975
FASEB J. 2014 Sep;28(9):4158-68
pubmed: 24928198
FASEB J. 2019 Dec;33(12):14147-14158
pubmed: 31647879
Sci Rep. 2017 Feb 13;7:42369
pubmed: 28205573
Mol Cancer Ther. 2014 Jan;13(1):165-78
pubmed: 24170768
Adv Exp Med Biol. 2019;1136:71-85
pubmed: 31201717
Carcinogenesis. 2014 Apr;35(4):840-8
pubmed: 24473118
Trends Mol Med. 2006 Sep;12(9):406-14
pubmed: 16899407
Carcinogenesis. 2013 Nov;34(11):2558-67
pubmed: 23836782
Cell Rep. 2017 Sep 12;20(11):2547-2555
pubmed: 28903036
Annu Rev Pathol. 2017 Jan 24;12:245-275
pubmed: 27959635
PLoS One. 2012;7(3):e33418
pubmed: 22428047
Exp Mol Med. 2019 Jun 20;51(6):1-17
pubmed: 31221981
FEBS Open Bio. 2020 May;10(5):789-801
pubmed: 32134564
Crit Rev Biochem Mol Biol. 2020 Oct;55(5):409-424
pubmed: 32878499
Mol Cancer. 2010 Jul 13;9:191
pubmed: 20626868
FEBS J. 2020 May;287(10):2070-2086
pubmed: 31693298
Melanoma Res. 2003 Oct;13(5):493-501
pubmed: 14512791
Nat Commun. 2020 Aug 17;11(1):4111
pubmed: 32807776
Nat Cell Biol. 2016 Oct;18(10):1090-101
pubmed: 27617932
Elife. 2017 Aug 02;6:
pubmed: 28767039
J Invest Dermatol. 2006 Dec;126(12):2687-96
pubmed: 16826166
J Natl Cancer Inst. 2004 Nov 17;96(22):1702-13
pubmed: 15547183
Clin Cancer Res. 2019 Apr 1;25(7):2206-2218
pubmed: 30563937
Transl Cancer Res. 2013 Oct 1;2(5):442-448
pubmed: 25599021
Cancer Lett. 2012 Nov 1;324(1):31-41
pubmed: 22659468
Mod Pathol. 2011 Aug;24(8):1036-45
pubmed: 21499230
J Leukoc Biol. 2001 Apr;69(4):522-30
pubmed: 11310837
Front Immunol. 2016 Feb 16;7:52
pubmed: 26909082
Biochim Biophys Acta. 2016 Nov;1863(11):2710-2718
pubmed: 27542908
Eur J Cancer. 2020 Feb;126:159-177
pubmed: 31866016
Springerplus. 2014 Aug 26;3:470
pubmed: 25221735
Mol Pharm. 2019 Nov 4;16(11):4530-4541
pubmed: 31617723
Int J Mol Sci. 2021 Jan 07;22(2):
pubmed: 33430277
Pigment Cell Melanoma Res. 2020 Jan;33(1):41-51
pubmed: 31310445
Mol Cancer Res. 2009 Apr;7(4):549-56
pubmed: 19372583
J Clin Pathol. 2016 Jun;69(6):472-83
pubmed: 26865640
Proc Natl Acad Sci U S A. 2015 Apr 7;112(14):4441-6
pubmed: 25792458
Front Immunol. 2014 Jul 28;5:358
pubmed: 25120544
Am J Pathol. 2019 Apr;189(4):900-910
pubmed: 30653955
Mol Cancer. 2018 Aug 17;17(1):124
pubmed: 30119675
Int J Nanomedicine. 2020 Mar 10;15:1677-1691
pubmed: 32214807
Acta Pharm Sin B. 2015 Sep;5(5):378-89
pubmed: 26579469
Cancer Res. 2014 May 1;74(9):2499-509
pubmed: 24491800
Int J Mol Sci. 2017 Nov 07;18(11):
pubmed: 29112174
Int J Dermatol. 2012 Oct;51(10):1263-7
pubmed: 22994674
Rom J Morphol Embryol. 2018;59(1):23-28
pubmed: 29940608
Pigment Cell Melanoma Res. 2019 Nov;32(6):792-808
pubmed: 31207090
Cancer Res. 2016 Mar 15;76(6):1381-90
pubmed: 26719539
J Invest Dermatol. 2006 Dec;126(12):2596-606
pubmed: 16810299
Oncogene. 2018 Mar;37(9):1192-1204
pubmed: 29238041
Cell Death Dis. 2015 Apr 02;6:e1711
pubmed: 25837487
Cancer Res. 2014 Dec 15;74(24):7250-9
pubmed: 25377469
Neuron. 2011 Jun 9;70(5):924-38
pubmed: 21658585
J Cell Physiol. 2013 Jun;228(6):1351-8
pubmed: 23184727
Cancer Lett. 2017 Jun 28;396:10-20
pubmed: 28288873
J Biol Chem. 2009 Jun 19;284(25):16767-16775
pubmed: 19386601
Mayo Clin Proc. 2011 Oct;86(10):981-90
pubmed: 21964175
Melanoma Res. 2007 Dec;17(6):400-9
pubmed: 17992124
Sci Rep. 2016 Jul 18;6:29914
pubmed: 27426915
Oncologist. 2008;13 Suppl 3:21-6
pubmed: 18458121
J Immunol. 2011 Aug 15;187(4):1970-6
pubmed: 21765015
ACS Med Chem Lett. 2015 Nov 10;7(1):28-33
pubmed: 26819661
Oncotarget. 2020 Sep 15;11(37):3443-3458
pubmed: 32973969
Eur J Immunol. 2016 Dec;46(12):2842-2851
pubmed: 27667124
Oncotarget. 2016 Feb 16;7(7):7816-28
pubmed: 26761211
Int J Cancer. 2010 Jul 1;127(1):207-19
pubmed: 19876915
Cancer Immunol Res. 2017 Jan;5(1):9-16
pubmed: 27941003
Nat Rev Cancer. 2004 Jun;4(6):437-47
pubmed: 15170446
Cancers (Basel). 2020 Dec 31;13(1):
pubmed: 33396270
J Clin Pathol. 2004 Oct;57(10):1009-14
pubmed: 15452150
N Engl J Med. 2006 Jul 6;355(1):51-65
pubmed: 16822996
Biomed Res Int. 2019 Jul 11;2019:3909102
pubmed: 31380420
Cancer Res. 2006 Jul 1;66(13):6699-707
pubmed: 16818644
Hypoxia (Auckl). 2015 Dec 11;3:83-92
pubmed: 27774485
ACS Appl Mater Interfaces. 2019 Dec 18;11(50):46536-46547
pubmed: 31751119
Neoplasma. 2019 Feb 17;66(3):427-436
pubmed: 30784290
Oncogene. 2016 Sep 22;35(38):5070-7
pubmed: 26973244
Biochim Biophys Acta Gen Subj. 2020 Dec;1864(12):129723
pubmed: 32861756
J Mol Med (Berl). 2014 Dec;92(12):1283-92
pubmed: 25120128
Altern Med Rev. 2010 Sep;15(3):264-72
pubmed: 21155627
Annu Rev Pathol. 2014;9:47-71
pubmed: 23937437
Sci Rep. 2018 Aug 27;8(1):12905
pubmed: 30150674
Oncotarget. 2017 Dec 5;8(70):115140-115152
pubmed: 29383148
Pharmacol Res. 2020 Aug;158:104885
pubmed: 32434051
Sci China Life Sci. 2017 Oct;60(10):1114-1124
pubmed: 29039125
Int J Oncol. 2014 Jan;44(1):78-90
pubmed: 24173371
Mol Ther Oncolytics. 2019 Nov 27;16:30-40
pubmed: 32258386
Oncotarget. 2016 May 17;7(20):29548-62
pubmed: 27121131
Clin Exp Metastasis. 1996 Mar;14(2):176-86
pubmed: 8605731
Biomedicines. 2017 May 09;5(2):
pubmed: 28536364
Sci Transl Med. 2020 Oct 28;12(567):
pubmed: 33115954
Transl Lung Cancer Res. 2013 Jun;2(3):152-9
pubmed: 25806228
Pigment Cell Melanoma Res. 2012 May;25(3):375-83
pubmed: 22360810
Oncol Lett. 2021 Feb;21(2):110
pubmed: 33376543
Oncotarget. 2014 May 15;5(9):2761-77
pubmed: 24811731
Mol Pharm. 2009 Jul-Aug;6(4):1041-51
pubmed: 19366234
J Physiol. 2005 Aug 15;567(Pt 1):225-38
pubmed: 15946960
Cell Mol Life Sci. 2018 Mar;75(6):1043-1056
pubmed: 29032501
Biochem Biophys Res Commun. 2019 Jul 12;515(1):85-91
pubmed: 31128917
Clin Exp Metastasis. 2014 Apr;31(4):423-33
pubmed: 24469963
Cells. 2020 Apr 16;9(4):
pubmed: 32316260
Front Immunol. 2019 Jun 06;10:925
pubmed: 31244820
Pathol Res Pract. 2013 Oct;209(10):640-7
pubmed: 23938031
Br J Dermatol. 2013 Nov;169(5):1049-55
pubmed: 23855428
J Immunother Cancer. 2019 Jun 13;7(1):152
pubmed: 31196219
Biofactors. 2019 May;45(3):401-415
pubmed: 30854715
Int J Hematol. 2012 May;95(5):457-63
pubmed: 22535382
J Biol Chem. 2011 Apr 15;286(15):13096-105
pubmed: 21345796
Cancer Res. 1989 Aug 15;49(16):4373-84
pubmed: 2545340
J Cell Biol. 2018 Feb 5;217(2):447-457
pubmed: 29233866
Acta Physiol (Oxf). 2019 Jan;225(1):e13105
pubmed: 29802798
Tumour Biol. 2016 Mar;37(3):4175-82
pubmed: 26490988
Int J Biochem Cell Biol. 2016 Dec;81(Pt A):121-132
pubmed: 27840154
Int J Oncol. 2017 May;50(5):1531-1540
pubmed: 28339028
Int J Mol Sci. 2020 Nov 07;21(21):
pubmed: 33171792
Oncotarget. 2017 Jul 4;8(27):44498-44510
pubmed: 28562340
Int J Clin Exp Pathol. 2014 Apr 15;7(5):2446-53
pubmed: 24966955
Crit Rev Biochem Mol Biol. 2000;35(2):71-103
pubmed: 10821478
Nat Commun. 2018 Dec 21;9(1):5426
pubmed: 30575721
Mol Biol Cell. 2005 Apr;16(4):1901-12
pubmed: 15689487
Am J Pathol. 2011 Dec;179(6):3020-31
pubmed: 21996677
J Clin Invest. 2015 Jun;125(6):2385-98
pubmed: 25961455
JAMA Ophthalmol. 2014 May;132(5):614-21
pubmed: 24626595
J Biol Chem. 2012 Aug 31;287(36):30664-76
pubmed: 22761435
Cancers (Basel). 2020 Oct 17;12(10):
pubmed: 33080820
Mol Cell Proteomics. 2013 Mar;12(3):736-48
pubmed: 23275444
Cancer Chemother Pharmacol. 2012 Jun;69(6):1487-98
pubmed: 22382881
Biol Pharm Bull. 2019;42(5):837-839
pubmed: 31061328
Lancet Oncol. 2002 Jan;3(1):35-43
pubmed: 11905603
Pathol Res Pract. 2020 Jan;216(1):152752
pubmed: 31791701
J Biol Chem. 2015 Sep 25;290(39):23670-9
pubmed: 26221040
J Mol Med (Berl). 2017 Dec;95(12):1341-1353
pubmed: 28929255
PLoS One. 2014 Aug 28;9(8):e105372
pubmed: 25166211
Cancer Res. 2000 Dec 15;60(24):7075-83
pubmed: 11156414
Front Cell Dev Biol. 2018 Sep 10;6:104
pubmed: 30250843
Cell Cycle. 2016 Jun 2;15(11):1462-70
pubmed: 27105345
Essays Biochem. 2007;43:165-78
pubmed: 17705800
Eur J Cancer. 2010 Apr;46(6):1159-69
pubmed: 20185296
Cell Death Dis. 2019 Feb 21;10(3):177
pubmed: 30792387
Transl Oncol. 2017 Dec;10(6):956-975
pubmed: 29078205
Nature. 2006 May 25;441(7092):437-43
pubmed: 16724055
J Immunoassay Immunochem. 2016;37(5):463-71
pubmed: 27175552